Recro to Present at H.C. Wainwright BioConnect 2022 Conference
Recro Pharma (REPH) has announced that CEO David Enloe will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Recro Pharma (REPH) has announced that CEO David Enloe will present at the H.C. Wainwright BioConnect 2022 Conference, taking place from January 10-13, 2022. The conference will be held virtually, and Enloe's presentation will be available online starting January 10. Interested parties can access the presentation via the 'Events' page on Recro's investor website, where an archived version will be available for 30 days. Recro is a leading contract development and manufacturing organization focused on small molecule therapeutic development.
Details
News Market Reaction – REPH
The recorded move for REPH in the trading session of this news was +1.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format.
Details for the corporate presentation are as follows:
- H.C. Wainwright BioConnect 2022 Conference
Conference Dates: January 10-13, 2022
Presentation Timing: Available online upon start of conference on Monday, January 10, 2022
Format: Virtual conference; webcast available
To access the webcast of the presentation, please do so by visiting the “Events” page in the Investor section of the Company’s website, www.recrocdmo.com. An archived webcast will be available on the Company’s website for 30 days.
About Recro
Recro (NASD: REPH) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.
In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.
For more information about Recro’s CDMO solutions, visit recrocdmo.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.